Weekly Spotlight - 09.01.25

Community

Share Your Story, Inspire Hope

Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured.

Latest News

FDA Approves First New Treatment for Classic Adrenal Disorder in 70 Years

The FDA has approved the first new drug in 70 years for classic congenital adrenal hyperplasia, a genetic disorder that affects hormone production. The drug, called isturisa, helps regulate cortisol levels, reducing the need for multiple daily medications and potentially improving quality of life for those with the condition.

New Study Highlights Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia Patients

Neurocrine Biosciences has published a study in the Expert Review of Endocrinology & Metabolism on traditional glucocorticoid treatment for classic congenital adrenal hyperplasia, highlighting its effects and implications for patients with this condition. The research aims to improve treatment outcomes and management strategies.

Neurocrine Biosciences Develops New Treatments for Rare Hormonal Disorder

Neurocrine Biosciences is researching new treatments for congenital adrenal hyperplasia (CAH), a genetic disorder affecting adrenal gland function. The company aims to develop more effective and convenient therapies to manage CAH symptoms and improve patients' quality of life. These potential treatments are in various stages of clinical trials.